Tim van Hauwermeiren
Founder en ARGENX SE .
Fortuna: 36 M $ al 31/03/2024
Perfil
Fundador de argenx SE, Tim van Hauwermeiren ocupa actualmente el cargo de presidente de Aelin Therapeutics NV y de director general y ejecutivo de argenx SE. También forma parte del consejo de administración de iTeos Therapeutics SA e iTeos Therapeutics, Inc. En el pasado ocupó el cargo de Jefe de Grupo en Procter & Gamble Co. y de Director Senior de Desarrollo de Negocio en Ablynx NV. Obtuvo un MBA en la Escuela de Administración de Vlerick Leuven Gent y un título de posgrado y una licenciatura en la Universidad de Gante.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
ARGEN-X SE
0.12% | 20/02/2024 | 71 986 ( 0.12% ) | 28 M $ | 31/03/2024 |
ARGENX SE ADR
0.03% | 31/08/2023 | 18 100 ( 0.03% ) | 7 M $ | 31/03/2024 |
ITEOS THERAPEUTICS, INC.
-.--% | 13/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Tim van Hauwermeiren
Empresas | Cargo | Inicio |
---|---|---|
ARGENX SE | Founder | 01/01/2008 |
ITEOS THERAPEUTICS, INC. | Director/Board Member | 01/06/2018 |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Director/Board Member | 27/06/2018 |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Chairman | - |
Antiguos cargos conocidos de Tim van Hauwermeiren.
Empresas | Cargo | Fin |
---|---|---|
RAYZEBIO, INC. | Director/Board Member | 26/02/2024 |
ABLYNX | Corporate Officer/Principal | - |
PROCTER & GAMBLE COMPANY | Corporate Officer/Principal | - |
Formación de Tim van Hauwermeiren.
Ghent University | Graduate Degree |
Vlerick Leuven Gent Management School | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 4 |
---|---|
PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
ARGENX SE | Health Technology |
ITEOS THERAPEUTICS, INC. | Health Technology |
RAYZEBIO, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Ablynx NV
Ablynx NV BiotechnologyHealth Technology Ablynx NV operates as a clinical stage biopharmaceutical company, which engages in the development of proprietary therapeutic proteins under the Nanobodies brand. It includes haematology, inflammation, infectious disease, autoimmune disease, oncology and immune-oncology. The company was founded by Mark Vaeck in 2001 and is headquartered in Ghent, Belgium. | Health Technology |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Aelin Therapeutics NV develops drugs for antibiotics and first-in-class therapeutics. The company is based in Leuven, Belgium. The Belgian company was founded in 2017. The CEO is Els Beirnaert. | Health Technology |
- Bolsa de valores
- Insiders
- Tim van Hauwermeiren